Literature DB >> 16621049

Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding.

Amy C Chess1, David J Bucci.   

Abstract

Kynurenic acid (KYNA) is a tryptophan metabolite synthesized and released by glia and recently shown to be a non-competitive antagonist of alpha7 nicotinic acetylcholine receptors at physiologically relevant concentrations, and NMDA receptors at higher concentrations. KYNA concentration is elevated in individuals with schizophrenia and those with Alzheimer's disease, two populations exhibiting cholinergic-related cognitive impairments. The present study investigated the effects of elevated KYNA concentration on conditioned stimulus processing in rats. For the first 2 days of the experiment, a subset of rats received intracerebroventricular infusions of either KYNA (0.1 microM) or vehicle and were either returned to the home cage or received non-reinforced presentations of a visual stimulus. All rats subsequently received presentations of the same visual stimulus followed by food reward during a 6-day training phase. In vehicle-treated rats, pre-exposure to the visual stimulus reduced orienting behaviour to the light (standing on the hind legs and orienting towards the visual stimulus) when it was later reinforced (i.e., conditioned orienting). In contrast, pre-exposure to the visual cue or 2 days of KYNA pretreatment reduced conditioned orienting behaviour. Finally, the reduction of orienting in KYNA-treated rats following pre-exposure was not as robust as in vehicle-treated rats. These results suggest that elevated KYNA levels can alter specific aspects of attentional processing of environmental stimuli and are discussed in terms of the potential contribution of KYNA to cognitive function and dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16621049     DOI: 10.1016/j.bbr.2006.03.006

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  36 in total

1.  3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia.

Authors:  Ruth Condray; George G Dougherty; Matcheri S Keshavan; Ravinder D Reddy; Gretchen L Haas; Debra M Montrose; Wayne R Matson; Joseph McEvoy; Rima Kaddurah-Daouk; Jeffrey K Yao
Journal:  Int J Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 5.176

2.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

3.  Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior.

Authors:  Michelle C Potter; Greg I Elmer; Richard Bergeron; Edson X Albuquerque; Paolo Guidetti; Hui-Qiu Wu; Robert Schwarcz
Journal:  Neuropsychopharmacology       Date:  2010-03-24       Impact factor: 7.853

4.  Repeated LPS Injection Induces Distinct Changes in the Kynurenine Pathway in Mice.

Authors:  M K Larsson; A Faka; M Bhat; S Imbeault; M Goiny; F Orhan; A Oliveros; S Ståhl; X C Liu; D S Choi; K Sandberg; G Engberg; L Schwieler; S Erhardt
Journal:  Neurochem Res       Date:  2016-05-10       Impact factor: 3.996

5.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

6.  Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor.

Authors:  Hui-Qiu Wu; Masahiro Okuyama; Yasushi Kajii; Ana Pocivavsek; John P Bruno; Robert Schwarcz
Journal:  Schizophr Bull       Date:  2014-03       Impact factor: 9.306

Review 7.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

8.  Targeting inflammation to influence cognitive function following spinal cord injury: a randomized clinical trial.

Authors:  D J Allison; A R Josse; D A Gabriel; P Klentrou; D S Ditor
Journal:  Spinal Cord       Date:  2016-06-21       Impact factor: 2.772

9.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

10.  The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia.

Authors:  Hannah F Iaccarino; Raymond F Suckow; Shan Xie; David J Bucci
Journal:  Schizophr Res       Date:  2013-09-30       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.